141 related articles for article (PubMed ID: 31037438)
21. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
22. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
23. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
Groenland SL; Katz D; Huitema ADR; Steeghs N
BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Arai H; Fukasawa N; Ueta F
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
[No Abstract] [Full Text] [Related]
25. ASO Author Reflections: Moving the Needle in Extremity and Trunk Soft Tissue Sarcoma.
Roland CL; van Houdt W; Gronchi A
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):899-900. PubMed ID: 32833151
[No Abstract] [Full Text] [Related]
26. ASO Author Reflections: Non-GIST Sarcoma Liver Metastasis: How to Use the Past and Present to Predict the Future.
Goumard C; Conrad C
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):926-927. PubMed ID: 30298322
[No Abstract] [Full Text] [Related]
27. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
[TBL] [Abstract][Full Text] [Related]
28. Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).
Ronellenfitsch U; Dimitrakopoulou-Strauss A; Jakob J; Kasper B; Nowak K; Pilz LR; Attenberger U; Gaiser T; Egerer G; Fröhling S; Derigs HG; Schwarzbach M; Hohenberger P
BMJ Open; 2016 Jan; 6(1):e009558. PubMed ID: 26739732
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib for both GIST and soft-tissue sarcoma.
Nishida T; Doi T
Lancet Oncol; 2016 May; 17(5):549-50. PubMed ID: 27068859
[No Abstract] [Full Text] [Related]
30. [Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?].
Agrafiotis AC; Prieto M; Verhaeghe JL; Siat J; Grosdidier G; Rios M
Rev Pneumol Clin; 2016 Oct; 72(5):293-295. PubMed ID: 27561973
[TBL] [Abstract][Full Text] [Related]
31. ASO Author Reflections: Location-Specific Staging in Sarcoma-A Step in the Right Direction.
Fisher SB; Roland CL
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):930-931. PubMed ID: 30324474
[No Abstract] [Full Text] [Related]
32. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
[TBL] [Abstract][Full Text] [Related]
33. ASO Author Reflections: Every Step Counts: Improved Survival of Retroperitoneal Sarcoma Patients During the Past 15 Years.
Callegaro D; Swallow CJ
Ann Surg Oncol; 2021 Mar; 28(3):1710-1711. PubMed ID: 33057862
[No Abstract] [Full Text] [Related]
34. ASO Author Reflections: Rationale for Organ Resection for Retroperitoneal Sarcomas.
Fairweather M; Raut CP
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):940-941. PubMed ID: 30377921
[No Abstract] [Full Text] [Related]
35. ASO Author Reflections: Retroperitoneal Soft Tissue Sarcoma: A Call for Collaboration and Scientific Inquiry.
Villano AM; Farma JM
Ann Surg Oncol; 2022 Apr; 29(4):2286-2287. PubMed ID: 34657199
[No Abstract] [Full Text] [Related]
36. ASO Author Reflections: Does a Nonsystematic Regarding Excision Approach After Complete Unplanned Excision of a Soft Tissue Sarcoma Impact Amputation Rate, Metastatic Risk, or Overall Survival?
Decanter G; Bonvalot S
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):768-769. PubMed ID: 31602576
[No Abstract] [Full Text] [Related]
37. ASO Author Reflections: Sarcoma Organoids: Neutralizing the Word "Rare" in Rare Cancers.
Forsythe SD; Sivakumar H; Erali RA; Skardal A; Votanopoulos KI
Ann Surg Oncol; 2022 Nov; 29(12):7368-7369. PubMed ID: 35778628
[No Abstract] [Full Text] [Related]
38. ASO Author Reflections: Towards Patient-Tailored Management of Extremity Soft Tissue Sarcoma.
Acem I; van de Sande MAJ; Verhoef C
Ann Surg Oncol; 2021 Nov; 28(12):7937-7938. PubMed ID: 33866469
[No Abstract] [Full Text] [Related]
39. Nursing considerations for patients with sarcoma on pazopanib therapy.
Holland J; Flaherty C
Clin J Oncol Nurs; 2015 Jun; 19(3):E59-62. PubMed ID: 26000592
[TBL] [Abstract][Full Text] [Related]
40. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
